IMPACT Medicom
Avsnitt

Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape

IMPACT Medicom
Dela

In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. 

Our Guest:
Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba.

If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com

This episode was funded by Eli Lilly, Canada. 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör IMPACT Medicom. Innehållet i podden är skapat av IMPACT Medicom och inte av, eller tillsammans med, Poddtoppen.